Atlas Trials

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

Clinical trial NCT02028455 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02028455
Sponsor
Seattle Children's Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
CD19+ Acute Leukemia
Start date
2014-02-11
Primary completion
2021-08-10
Enrollment
167

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.